GLP-1 receptor agonists appear safe and well-tolerated in IBD patients — a population excluded from all pivotal trials — with observational data suggesting they may even reduce hospitalizations, surgery, and steroid use alongside delivering weight and metabolic benefits.
No increased IBD flaresAcross multiple datasets, GLP-1 drugs were not associated with increased IBD exacerbations, and large registries showed reduced corticosteroid use, hospitalizations, and surgery among GLP-1 users with IBD
What the researchers found
Across 14 studies (13 retrospective cohort) of GLP-1 receptor agonists in adults with IBD:
• 10 of 14 studies reported significant reductions in body weight, BMI, or percent weight loss
• 4 studies demonstrated metabolic improvements: decreased HbA1c and favorable lipid changes
• GLP-1 RA use was NOT associated with increased IBD exacerbations across multiple datasets
• Several large registries reported REDUCED risks among GLP-1 users of: corticosteroid use, hospitalization, and surgery
• Adverse events were primarily gastrointestinal, consistent with non-IBD populations (no excess GI toxicity from underlying IBD)
• The findings suggest potential anti-inflammatory or disease-modifying effects, though this requires prospective confirmation
Why it matters
Obesity affects up to 40% of IBD patients and worsens disease outcomes, but doctors have been reluctant to prescribe GLP-1 drugs because IBD patients were systematically excluded from the clinical trials that got these drugs approved. This first systematic review provides the evidence base that gastroenterologists need to feel confident prescribing these effective weight loss medications to their IBD patients.
How the study worked
Systematic review following PRISMA guidelines (registered: PROSPERO CRD42025628850). Searched MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov through September 9, 2025. Included studies evaluating GLP-1 RAs in adults with IBD. Primary outcomes: weight-related measures. Secondary outcomes: metabolic parameters, IBD activity, and safety. Risk of bias assessed using JBI checklists. 14 studies included (13 retrospective cohort, 1 other design).
What this study cannot tell us
Nearly all studies (13/14) were retrospective cohort designs, which cannot establish causation. Selection bias is a concern — healthier IBD patients may have been more likely to receive GLP-1 drugs. No randomized controlled trial data exist in IBD populations. The reduced hospitalization/surgery signals could reflect confounding rather than drug effects. Sample sizes and follow-up durations varied. Different GLP-1 drugs, doses, and IBD subtypes were pooled together.
How to read the evidence
This is a well-conducted systematic review following PRISMA guidelines with PROSPERO registration. However, the underlying evidence is almost entirely observational (13/14 retrospective cohort studies), limiting causal conclusions. The consistent direction of findings across multiple studies strengthens confidence, but prospective RCTs in IBD are needed for definitive evidence.
When this study was published
Published in 2026 with literature search through September 2025, this is a very current systematic review addressing an urgent clinical question as GLP-1 prescribing expands into IBD populations.
The bigger picture
GLP-1 receptor agonists have known anti-inflammatory properties beyond their metabolic effects, and this may explain the observed benefits in IBD. GLP-1 receptors are expressed on immune cells, and preclinical studies have shown anti-inflammatory effects in gut models. If prospective trials confirm that GLP-1 drugs not only don't worsen IBD but actually improve disease outcomes, this would represent a paradigm shift — a single drug class treating both obesity and inflammatory bowel disease simultaneously.
Questions still open
- Do GLP-1 drugs have direct anti-inflammatory effects in the gut that could benefit IBD independent of weight loss?
- Which IBD patients benefit most from GLP-1 therapy — those with obesity-driven inflammation or all IBD subtypes?
- Should prospective IBD-specific GLP-1 trials be designed, and what should the primary endpoints be?
Common questions
Can people with Crohn's or ulcerative colitis safely take GLP-1 drugs?
Why were IBD patients excluded from GLP-1 clinical trials?
Read the original research
Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.
Alimentary pharmacology & therapeutics, 63(1), 17-39
Citation
Maracle, Brooke; Quan, Steven; Hamilton, Patrick; Shaikh, Asma; Hazra, Deepan; Lorenzetti, Diane L; Gold, Stephanie L; Raman, Maitreyi; St-Pierre, Joëlle. (2026). Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.. Alimentary pharmacology & therapeutics, 63(1), 17-39. https://doi.org/10.1111/apt.70485